The Burkholderia cepacia complex includes 9 genomovars. The relative virulence of each is unknown. Host and pathogen features associated with mortality were evaluated among patients with B. cepacia complex bacteremia. Cases were ascertained through review of blood culture results for the period of May 1996 through May 2002. Isolates were identified to species level with 16S rDNA and recA-based species-specific polymerase chain reaction analyses and recA restriction fragment-length polymorphism. Strain typing was performed with pulsed-field gel electrophoresis. Fifty-three patients with B. cepacia complex bacteremia were identified; only 9 (17%) had cystic fibrosis. Twenty-five patients (47%) died within 14 days of bacteremia. After controlling for comorbid conditions and therapeutic interventions, 2 outbreak-related strains of Burkholderia cenocepacia (genomovar III) were associated with 14-day mortality (odds ratio, 5.5; 95% confidence interval, 1.20-25.02). B. cenocepacia is an emerging nosocomial pathogen. Certain strains are associated with an enhanced capacity for interpatient spread and poor outcome.
VII), Burkholderia anthina (genomovar VIII), and
Burkholderia pyrrocinia (genomovar IX) [1, 2] . The organisms are gram-negative, nonfermenting, aerobic bacilli; the type species of this group was originally recognized as a plant pathogen [3] . Colonization and subsequent infection in patients with cystic fibrosis (CF) with B. cepacia complex has been associated with poor outcomes, including accelerated decline in pulmonary function and early death [4, 5] .
Although organisms belonging to each genomovar have been recovered from patients with CF, recent data indicate that the majority of clinical isolates are B. cenocepacia (genomovar III) and B. multivorans (genomovar II) [6] [7] [8] . In addition, recent studies suggest that there may be an increase in morbidity and mortality among persons colonized or infected with B. cenocepacia [9] [10] [11] . Furthermore, several epidemiological studies have indicated that certain B. cepacia complex strains are transmissible between patients and that cross-infection probably occurs by direct person-to-person spread [12] . On the basis of these observations, it has been speculated that, in addition to the possibility of genomovar-specific virulence factors, certain genomovars may be more likely to spread among CF cohorts or among groups of hospitalized patients.
The effect of B. cepacia complex infections in populations without CF has not been well characterized, and few studies have evaluated large numbers of patients with bacteremia. We investigated a relatively large cohort of patients with B. cepacia complex bacteremia, most of whom did not have CF, who were identified at our institution over a 6-year period. Many of the cases were associated with 2 prolonged clonal outbreaks. This study describes clinical characteristics and evaluates host-and pathogen-specific features associated with mortality. Data collection. By use of a standardized questionnaire, epidemiological and clinical data were abstracted from paper charts and electronic databases. Information on patients' vital signs, procedure dates, and pharmacy use was obtained from existing hospital databases.
PATIENTS, MATERIALS, AND METHODS

Cohort
Definitions. A patient with B. cepacia complex bacteremia was defined as any patient with systemic signs of infection (temperature у38.0ЊC or !36.0ЊC or acute deterioration in clinical condition) and у1 blood culture that yielded an isolate confirmed to be B. cepacia complex. The date of onset of bacteremia was defined as the date of obtainment of the sample that yielded a patient's first blood culture positive for B. cepacia complex. Comorbid conditions were considered to be present if they were noted at the time of admission to the hospital or, in patients who received organ transplants, if they occurred during the hospitalization before bacteremia. Surgery other than organ transplantation was included if the procedure occurred р4 weeks before B. cepacia complex bacteremia. For the purposes of analysis, patients were considered febrile (temperature, у38.0ЊC) or hypotensive (mean arterial pressure, !70 mm Hg) if these symptoms were documented within 24 h of bacteremia. Persistent fever was defined as a temperature of у38.0ЊC lasting 17 days beyond the date of onset of bacteremia.
Sepsis and septic shock were defined according to published consensus criteria [13] 10 .0 ϫ 10 defined as a serum creatinine у2.0 mg/dL; and acute liver dysfunction was defined as a serum bilirubin level of у2.0 mg/ dL or a serum transaminase level of 13 times the upper limit of normal on the day of bacteremia.
Appropriate antibiotics included any to which an isolate was susceptible provided for at least 48 h within 2 weeks before or 1 week after bacteremia. Primary bacteremia refers to cases in which no identifiable source of bloodstream infection could be recognized or to presumed catheter-related cases, in accordance with Centers for Disease Control and Prevention guidelines [14] . Patients with B. cepacia complex bacteremia arising from a respiratory source refers to patients with infiltrates on chest radiographs from whom B. cepacia complex was isolated from a respiratory specimen before or coincident with bacteremia. As a measure of chronic illness, a modified Charlson clinical comorbidity index was calculated at the time of hospital admission [15] . Patients received 1 point for coronary artery disease, congestive heart failure, cerebrovascular disease, obstructive pulmonary disease, pulmonary fibrosis, pulmonary hypertension, or HIV infection; 2 points for chronic renal failure or hematological malignancy; and 3 points for chronic liver failure. The severity of illness was also graded with the APACHE II scoring system at the onset of bacteremia [16] . B. cepacia complex was considered to be multidrug resistant when an isolate was resistant to all agents in у2 of the following 3 categories: b-lactam antibiotics, aminoglycosides, and fluoroquinolones. The primary outcome was 14-day in-hospital mortality.
Microbiological and molecular analysis. Blood samples were prospectively obtained for culture and processed according to standard practice. Gram-negative, oxidase-positive, nonfermenting rods were preliminarily identified as B. cepacia complex by cell wall analysis with gas-liquid chromatography (MIDI System; Microbial ID). Antimicrobial susceptibilities were determined with a commercial minimal inhibitory concentration plate (Dade Microscan Negative Combo Panel Type 12; Dade Behring) and the disk diffusion method, when indicated. Susceptibility was interpreted according to the recommendations of the NCCLS for non-Enterobacteriaceae [17, 18] . Isolates were frozen and stored at Ϫ70ЊC and subsequently identified to the species level with 16S rDNA and recA PCR analyses and recA restriction fragment-length polymorphism assay, as described elsewhere [19, 20] . For strain typing, we performed macrochromosomal pulsedfield gel electrophoresis (PFGE) restriction fragment-length polymorphism analysis on all isolates by means of protocols described previously with a SpeI endonuclease digestion followed by electrophoresis in 1% agarose for 19.5 h on a CHEF Mapper system (Bio-Rad Laboratories) [21] . Strain characterization among PFGE patterns was determined visually by the method of Tenover et al. [22] .
Statistical analysis. Data were entered into a database with EpiInfo, version 6.0 (Centers for Disease Control and Prevention). For bivariable analyses, we determined relative risk (RR) of 14-day mortality with 95% CIs. Two-sided P values were calculated by the x 2 test or Fisher's exact test for ordinal and dichotomous variables. Continuous variables were compared by 2-sided Wilcoxon rank sum test or Student's t test. Multivariable logistic regression was performed using SAS software, version 8.2 (SAS Institute). The final model included covariates that were potential confounding variables or were associated with the outcome with on bivariable analysis. Variables P ! .1 were removed in a stepwise manner, and final associations were recorded as OR with 95% CIs. All covariates were checked for confounding and collinearity. If the addition of a confounding variable affected the b-coefficient of a covariate by 110%, it remained in the model.
RESULTS
We identified 60 patients from whom 102 separate blood isolates of putative B. cepacia complex were recovered. Isolates from 4 of these patients were not available for confirmation. Three additional patients were excluded from the study after molecular analysis showed that 2 were actually infected with Pandoraea species and the other was infected with a Ralstonia species. Of the remaining 53 patients, 25 (47%) died within 14 days of bacteremia. The relative risk of death based on demographic data and selected comorbid conditions is shown in table 1.
The patients' ages ranged from 24 days to 82 years (mean, 46.4 years), and the mean age of those who died within 14 days of bacteremia was modestly higher than that of those who survived (50.9 years vs. 45.7 years;
). The cohort was P p .38 predominantly female (55%) and white (71%), but there was no difference in mortality rate by sex or race. All enrolled persons were hospitalized, and 41 (77%) were being cared for in an intensive care unit at the time of bacteremia with B. cepacia complex. The median duration of hospitalization before Clinical and laboratory values and hospital interventions, by 14-day mortality rate, among a ). P p .22 The 9 patients (17%) with CF were significantly less likely to die within 14 days of bacteremia than was the remainder of the cohort (case fatality rate [CFR], 11% vs. 55%; RR, 0.51; 95% CI, 0.34-0.76). Although receipt of a solid-organ transplant was not associated with a poor outcome from bacteremia, the 12 lung transplant recipients were less likely to die during the first 14 days after bacteremia than was the remainder of the cohort (CFR, 15% vs. 58%; RR, 0.53; 95% CI, 0.34-0.81). Of note, 8 (67%) of 12 patients receiving lung transplants had CF. All 5 bone marrow transplant recipients died soon after bacteremia (CFR, 100%; RR, undefined;
). Although P p .01 other chronic illnesses were frequent among patients in the cohort, neither individual illnesses nor the overall Charlson score was significantly associated with death.
The relationships between clinical signs, laboratory findings, and hospital interventions and the risk of death are shown in table 2. In addition to having chronic illnesses, most patients were also acutely ill. Forty-one patients had undergone recent surgery, including 13 thoracic procedures and 13 abdominal procedures. Forty-two patients (79%) were receiving mechanical ventilatory support, and 23 (43%) had undergone tracheostomy by the time of bacteremia. None of these factors were associated with mortality.
Patients with a primary bacteremia had significantly worse outcomes than patients with a known (usually pulmonary) source (CFR, 70% vs. 33%; RR, 2.22; 95% CI, 1.09-4.52). Fortyfive patients (85%) had a documented fever within 24 h surrounding the date of bacteremia, and 20 (38%) met the definition of septic shock. However, only persistence of fever for 17 days was associated with an increased risk of death (RR, 2.80; 95% CI, 1.24-6.33). As expected, the APACHE II score calculated at the time of bacteremia was associated with mortality ( ). P p .01 Fifty patients (94%) had indwelling central venous catheters within 2 weeks before or at the time of bacteremia. Removal of central lines or changing central line placement within 7 days after B. cepacia complex bacteremia was associated with reduced mortality (CFR, 32% vs. 68%; RR, 0.46; 95% CI, 0.23-0.94). However, after the exclusion of patients who died within 24 h of bacteremia and therefore did not have adequate opportunity for this intervention, the association did not reach statistical significance (CFR, 30% vs. 53%; RR, 0.61; 95% CI, 0.32-1.17). Patients with multiple days of bacteremia were more likely to have CF than those patients with bacteremia documented on only a single day (40% vs. 8%; RR, 5.07; 95% CI, 1.45-17.69).
Forty-seven patients (89%) received antibiotics within 2 weeks before bacteremia; 31 (58%) received у1 antibiotic to which their isolate was susceptible. Although previous treatment with an antibiotic to which the isolate was susceptible was not associated with improved outcome, initiation of therapy with trimethoprim-sulfamethoxazole after isolation of B. cepacia complex from blood was associated with reduced mortality (RR, 0.62; 95% CI, 0.39-0.98). No other antibiotic provided after bacteremia was associated with improved outcome.
The influence of pathogen specific factors on mortality is shown in table 3. Forty-four isolates (83%) were susceptible to trimethoprim-sulfamethoxazole, the usual drug of choice. Isolates recovered from 17 patients (32%) with bacteremia were considered to be multidrug resistant, but these isolates were not associated with a higher likelihood of death.
Molecular speciation demonstrated that B. cenocepacia (genomovar III) accounted for 39 (74%) of 53 cases of B. cepacia complex bacteremia and 21 (84%) of the 25 deaths. B. cenocepacia was associated with an increased risk of 14-day mortality relative to other genomovars (CFR, 54% vs. 29%; RR, 1.55; 95% CI, 0.96-2.49). Furthermore, molecular subtyping by PFGE demonstrated that 2 strains of B. cenocepacia (outbreak strains A and B) accounted for 27 (51%) of 53 bacteremias and 18 (72%) of 25 deaths. These 2 strains were associated with 2 prolonged and concurrent outbreaks during the study period and were genotypically distinct (figure 1).
Outbreak A occurred from August 1997 through April 2001 and involved 18 patients and 12 deaths (67%) and was significantly associated with a higher risk of death (CFR, 67% vs. 37%; RR, 2.32; 95% CI, 1.02-5.27). Outbreak B occurred from November 1996 through February 2000 and involved only 9 patients and 6 deaths (67%), but the association between this strain and mortality was not statistically significant. Investigation by the study team failed to reveal a point source for these outbreaks (data not shown). In addition, neither of these strains was similar to the "epidemic" clones previously identified in the United States (data not shown). When data were analyzed together, it was found that the 27 patients with bacteremia caused by the 2 outbreak strains (A and B) died faster and more frequently than the 26 patients infected with other strains (CFR, 67% vs. 27%; RR, 2.32; 95% CI, 1.28-4.21) (figure 2). These latter 26 patients were infected with 12 unique strains of B. cenocepacia (genomovar III), 4 strains of genomovar I (isolated from 5 patients), 3 unique strains of B. multivorans (genomovar II; isolated from 6 patients), a single isolate of B. stabilis (genomovar IV), and 2 strains of B. vietnamiensis (genomovar V). None of the other genomovars was associated with 14-day mortality.
In the final multivariable models, after controlling for sex, comorbid conditions (as represented by our modified Charlson score and CF), and therapeutic interventions (including initiation of trimethoprim-sulfamethoxazole after identification of B. cepacia complex bacteremia), neither strain A (OR, 3.6; 95% CI, 0.75-17.40) nor strain B (OR, 2.2; 95% CI, 0. 35-14.25) reached statistical significance because of insufficient power. However, because these 2 outbreak strains had clinically unique epidemiology and transmissibility and had a similar effect on 14-day mortality, they were analyzed together as a single variable in the multivariable model. When combined together in multivariable analysis, the 2 outbreak strains were strongly associated with 14-day mortality (OR, 5.5; 95% CI, 1.20-25.02).
DISCUSSION
This study, which describes a cohort of 53 primarily non-CFaffected patients identified over 6 years, is the largest investigation of B. cepacia complex bacteremia and the first to document high rates of attributable mortality in patients without CF. In addition, molecular typing confirmed that 2 strains of B. cenocepacia (genomovar III) were responsible for prolonged concurrent outbreaks accounting for 51% of all cases of B. cepacia complex bacteremia and 72% of deaths. The remaining cases represented primarily sporadic disease.
Although B. cepacia complex is a well-described nosocomial pathogen among patients without CF, bacteremia and pneumonia predominantly occur as a result of acute, point-source outbreaks [23] [24] [25] [26] [27] [28] [29] [30] [31] . Most reported outbreaks involved small numbers of patients. In contrast to the increased mortality reported among B. cepacia complex-colonized patients with CF, case-fatality rates for these point source outbreaks are usually extremely low. Epidemiological studies did not link the outbreaks described in this report to a point source.
We report a much higher overall case-fatality rate than did the other large investigation of B. cepacia complex bacteremia [32] . The older study preceded current identification capabilities and therefore may have represented a range of organisms. The increased case-fatality rate in the current study reflects a severely ill population; most of the patients had significant underlying morbidity or risk factor, including bone marrow or solid-organ transplants. Because the aim of this study was to identify predictors of mortality attributable to virulent strains of B. cepacia complex bacteremia, we chose to study 14-day mortality. We believed that analyses involving 30-day mortality or overall in-hospital mortality would have identified predictors of mortality primarily associated with underlying severity of illness, as opposed to B. cepacia complex bacteremia.
Notably, compared with patients with CF, patients without CF were at increased risk for death. Patients without CF were older and less likely to have been previously colonized by B. cepacia complex. It is possible that these patients without CF were less likely to have preexisting antibodies than were patients with CF. This reduced immunity might have led to a delayed immune response to B. cepacia complex bacteremia.
The strong association between B. cenocepacia infection and 14-day mortality in this study (84% of deaths occurred in patients with B. cenocepacia bacteremia) is consistent with 2 recent uncontrolled studies among small populations of lung transplant recipients with CF [9, 10] . However, although these studies suggested an association between genomovar III (B. cenocepacia) and poor outcome, they were limited by sample size. Aris et al. [10] asserted that virulence was not strain specific because the sputum and blood genomovar III (B. cenocepacia) isolates recovered from patients who died were discordant strains. However, no previous studies have documented large numbers of bloodstream infections caused by B. cenocepacia. The current study demonstrated a strong association between bacteremia caused by 2 outbreak strains of B. cenocepacia and an increased risk for 14-day mortality. These results suggest that virulence factors may not be distributed uniformly through B. cenocepacia. This is the first study to demonstrate an association of increased transmissibility with increased virulence in B. cepacia complex. The reason for B. cenocepacia's apparent virulence and epidemic potential remains elusive. Transmission of B. cepacia complex has been demonstrated among patients with CF [12, 33] , patients without CF [34] , and between patients with and patients without CF [35] . However, the outbreak strains identified in this study were different from previously identified epidemic clones (data not shown).
This study also identified an association between 14-day mortality and several comorbid conditions and prolonged fever. In addition, treating patients with trimethoprim-sulfamethoxazole was associated with improved outcomes. This finding is consistent with the 2 published studies of endemic B. cepacia complex bacteremia, which also described an association between treatment with trimethoprim-sulfamethoxazole and improved outcome [32, 35] .
B. cenocepacia (genomovar III) is an important emerging nosocomial pathogen in both persons with CF and persons without CF that may result in substantial associated mortality, but virulence appears to be strain specific. This organism is difficult to treat because it is often resistant to multiple antibiotic classes. Further epidemiological studies are needed to identify risk factors for the acquisition of this organism and strategies for prevention of colonization and infection. Microbiological and molecular investigations into pathogenesis, virulence factors, and mechanisms of resistance may be important to direct future initiatives focused on prevention and therapy. Removal of all central venous lines and initiation of trimethoprim-sulfamethoxazole, specifically when B. cepacia complex is suspected, may be warranted pending final identification and susceptibility testing.
